Sessa Concetto, Galeano Dario, Alessandrello Ivana, Aprile Giorgio, Distefano Giulio, Ficara Vincenzo, Giglio Elisa, Musumeci Stella, Pocorobba Barbara, Zuppardo Carmelo, Musso Salvatore, Granata Antonio
U.O.C Nefrologia e Dialisi, P.O. "Maggiore" di Modica. Azienda Sanitaria Provinciale di Ragusa, Ragusa.
U.O. Radiologia I, Dipartimento di Scienze Mediche, Chirurgiche e Tecnologie Avanzate "G.F. Ingrassia", Università di Catania, Catania.
G Ital Nefrol. 2019 Jul 24;36(4):2019-vol4.
Osteoporosis affects a segment of the population in which Chronic Kidney Disease is also greatly represented. Nephropathic patients may present peculiar biochemical abnormalities related to Chronic Kidney Disease, defining the Mineral and Bone Disorder. This kind of anomalies, in the worst scenarios, configure the typical histomorphology patterns of Renal Osteodystrophy. Scientific Societies of Endocrinology have established therapy guidelines for patients with osteoporosis only based on the glomerular filtration rate and recommend avoiding the use of some drugs for the more advanced classes of nephropathy. However, there is no clear therapeutic approach for patients with advanced nephropathy and bone abnormalities. In this paper we propose a systematic review of the literature and present our proposal for managing patients with advanced nephropathy, based on eGFR and on presence of Mineral and Bone Disorder.
骨质疏松症影响着一部分人群，而慢性肾脏病在这部分人群中也极为常见。肾病患者可能会出现与慢性肾脏病相关的特殊生化异常，这被定义为矿物质和骨代谢紊乱。在最糟糕的情况下，这类异常会呈现出肾性骨营养不良的典型组织形态学模式。内分泌学科学学会仅根据肾小球滤过率为骨质疏松症患者制定了治疗指南，并建议避免为更晚期的肾病患者使用某些药物。然而，对于晚期肾病和骨异常患者，目前尚无明确的治疗方法。在本文中，我们对文献进行了系统综述，并基于估算肾小球滤过率（eGFR）以及矿物质和骨代谢紊乱的存在情况，提出了我们对晚期肾病患者的管理建议。
